---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-117571"
form_type: "8-K"
ticker: "IXHL"
cik: "0001873875"
company_name: "Incannex Healthcare Inc."
filed_at: "2025-12-03T23:59:59+00:00"
generated_at: "2026-05-16T15:26:26.254301+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# FDA grants Fast Track designation to Incannex's IHL-42X for obstructive sleep apnea

## Summary
- FDA Fast Track designation for Incannex's IHL-42X for obstructive sleep apnea (OSA).
- Phase 2 RePOSA study showed up to 83% reduction in AHI; safety and patient-reported outcomes positive.
- Fast Track enables rolling NDA submission, more FDA interaction, and potential Accelerated Approval.
- Incannex expects to receive FDA feedback on Phase 2 data and map path to late-stage development.

## SEC filing metadata
- accession: 0001213900-25-117571
- form_type: 8-K
- ticker: IXHL
- cik: 0001873875
- company_name: Incannex Healthcare Inc.
- filed_at: 2025-12-03T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1873875/000121390025117571/0001213900-25-117571-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1873875/000121390025117571/ea0268145-8k_incannex.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-117571
- JSON: https://secwatch.observer/filing/0001213900-25-117571.json
- Plain text: https://secwatch.observer/filing/0001213900-25-117571.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.